Wang J, Michel V, Leclerc C, Hofnung M, Charbit A
Unité de Programmation Moléculaire and Toxicologie Génétique-CNRS URA 1444, Département de Biotechnologies, Institut Pasteur, Paris, France.
Vaccine. 1999 Jan;17(1):1-12. doi: 10.1016/s0264-410x(98)00153-4.
We previously developed a general procedure which allows the genetic coupling of a chosen foreign linear epitope in different 'permissive' sites of a carrier protein. By using the outer membrane protein LamB of Escherichia coli K12 as a carrier, we were able to express a number of different foreign epitopes at the bacterial surface. In the present work, taking advantage of the recent determination of the crystal structure of LamB, we inserted two model B-cell epitopes i.e.--the C3 epitope from poliovirus (residues 93 to 103 of VP1) and the preS2 epitope from hepatitis B virus, (residues 132 to 145)--at the tip of the most distal and largest surface exposed region of LamB (after residues 386, into loop L9). We also used two previously constructed LamB hybrids, corresponding to the insertion of the C3B or preSB epitope into permissive site 153 (lying in the middle of the fourth surface loop of LamB), to construct two LamB proteins corresponding to the simultaneous insertion of the two different epitopes (with one epitope per site). The LamB hybrids were placed under the control of the anaerobically inducible pnirB promoter and expressed in a LamB-negative derivative of the aroA attenuated strain of S. typhimurium, SL3261. In vitro, the recombinant proteins were expressed at a high level (up to 10% of whole cell proteins) and in vivo the recombinant plasmids were stably maintained. For both epitopes, genetic coupling at site 386 appeared to be more favorable for the induction of anti-epitope antibodies than coupling at site 153. Moreover, the LamB hybrid corresponding to the simultaneous insertion of the preSB epitope at site 153 and of the C3B epitope at site 386 allowed the induction of both anti-poliovirus and anti-hepatitis B antibodies.
我们之前开发了一种通用方法,可实现将选定的外源线性表位在载体蛋白的不同“允许”位点进行基因偶联。通过使用大肠杆菌K12的外膜蛋白LamB作为载体,我们能够在细菌表面表达多种不同的外源表位。在本研究中,利用最近测定的LamB晶体结构,我们将两个模型B细胞表位,即脊髓灰质炎病毒的C3表位(VP1的93至103位氨基酸残基)和乙型肝炎病毒的前S2表位(132至145位氨基酸残基),插入到LamB最远端且最大的表面暴露区域的顶端(386位氨基酸残基之后,进入环L9)。我们还使用了两个先前构建的LamB杂种,它们分别对应于将C3B或前S2B表位插入允许位点153(位于LamB第四表面环的中间),来构建两个LamB蛋白,分别对应于同时在两个不同位点插入两种不同表位(每个位点一个表位)。将LamB杂种置于厌氧诱导型pnirB启动子的控制下,并在鼠伤寒沙门氏菌aroA减毒株SL3261的LamB阴性衍生物中表达。在体外,重组蛋白高水平表达(高达全细胞蛋白的10%),在体内重组质粒能稳定维持。对于这两种表位,在386位点进行基因偶联似乎比在153位点偶联更有利于诱导抗表位抗体。此外,对应于在前S2B表位在153位点和C3B表位在386位点同时插入的LamB杂种能够诱导产生抗脊髓灰质炎病毒和抗乙型肝炎抗体。